share_log

UBS Adjusts CARsgen Therapeutics' Price Target to HK$34.50 From HK$38, Keeps at Buy

UBS Adjusts CARsgen Therapeutics' Price Target to HK$34.50 From HK$38, Keeps at Buy

瑞銀將CarsGen Therapeutics的目標股價從38港元調整至34.50港元,維持買入水平
MT Newswires ·  2022/08/25 17:27

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論